6785 Stock Overview
A drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Alar Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$151.00 |
| 52 Week High | NT$445.50 |
| 52 Week Low | NT$122.50 |
| Beta | 0.12 |
| 1 Month Change | 19.84% |
| 3 Month Change | -0.66% |
| 1 Year Change | -63.57% |
| 3 Year Change | 189.27% |
| 5 Year Change | n/a |
| Change since IPO | 235.56% |
Recent News & Updates
Shareholder Returns
| 6785 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.7% | -1.4% | 2.6% |
| 1Y | -63.6% | 8.2% | 23.3% |
Return vs Industry: 6785 underperformed the TW Pharmaceuticals industry which returned 7.4% over the past year.
Return vs Market: 6785 underperformed the TW Market which returned 22.3% over the past year.
Price Volatility
| 6785 volatility | |
|---|---|
| 6785 Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.9% |
| 10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 6785's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6785's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 22 | Yung-Shun Wen | www.alarpharm.com |
Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. The company develops ALA-1000 for the treatment of opioid use disorder. Its pre-clinical stage product includes ALA-1300 and ALA-2000 for the treatment of opioid use disorder; ALA-4000 to treat Parkinson’s disease; ALA-3000 for treating treatment-resistant depression; and ALA-5000 to treat schizophrenia.
Alar Pharmaceuticals Inc. Fundamentals Summary
| 6785 fundamental statistics | |
|---|---|
| Market cap | NT$10.09b |
| Earnings (TTM) | NT$400.72m |
| Revenue (TTM) | NT$474.29m |
25.2x
P/E Ratio21.3x
P/S RatioIs 6785 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6785 income statement (TTM) | |
|---|---|
| Revenue | NT$474.29m |
| Cost of Revenue | NT$2.03m |
| Gross Profit | NT$472.26m |
| Other Expenses | NT$71.54m |
| Earnings | NT$400.72m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.00 |
| Gross Margin | 99.57% |
| Net Profit Margin | 84.49% |
| Debt/Equity Ratio | 0% |
How did 6785 perform over the long term?
See historical performance and comparisonDividends
1.0%
Current Dividend Yield24%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 04:25 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alar Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Weiyu Li | Capital Securities Corporation |